🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06733740
Recruiting Observational

Ultrasound-guided Thermal Ablation for Papillary Thyroid Carcinoma

NCT06733740 · tracked via the Priya Life Science China tracker
Sponsor
Chinese PLA General Hospital
Phase
Observational
Started
2024-12-10
Last updated
2025-02-14

Condition(s) studied

Papillary Thyroid Cancer

Investigational drug(s) / intervention(s)

ultrasound-guided thermal ablation

ultrasound-guided thermal ablation: ultrasound-guided thermal ablation to treat tumor

Study summary

To evaluate long-term outcomes of ultrasound-guided thermal ablation for the treatment of papillary thyroid carcinoma

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: 1. patients age between 18 and 80 year old, both sex 2. papillary thyroid carcinoma confirmed by core-needle biopsy or fine-needle aspiration 3. the largest diameter ≤2.0 cm 4. no clinical or imaging evidences of extrathyroidal extension, lymph node metastasis and distant metastasis on ultrasound, neck and chest CT 5. follow-up period ≥12 months Exclusion Criteria: 1. patients with convincing evidence of aggressive papillary thyroid carcinoma or other type of thyroid cancer by biopsy 2. history of neck radiation 3. coagulation disorder, serious heart, respiratory, liver, or renal failure 4. dysfunction of the vocal cord on the opposite side

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Chinese PLA General Hospital Beijing Beijing Municipality Recruiting

More Chinese PLA General Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06733740 on ClinicalTrials.gov ↗ ← All trials in China